Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK-GDT
- Development stage
- Preclinical
- Lead developer
- Enochian Biosciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NK-GDT is an investigational **allogeneic cellular immunotherapy** being developed by **Enochian Biosciences** for **HIV infection**. The product consists of **donor-derived natural killer cells and gamma delta T cells** collected from another person and administered as an adoptive immune-cell therapy intended to restore or augment antiviral immune control. Based on the provided context, the program has been described as a novel treatment for people with HIV who have failed to achieve viral suppression with antiretroviral therapy, with a reported case of virologic control during 155 days of treatment in a heavily treatment-experienced patient. Its proposed mechanism is immune-mediated control of HIV through the antiviral and cytotoxic activity of infused NK cells together with gamma delta T-cell activity.
- Other names
- Natural killer and gamma delta T-cell therapy
Beyond the preview
Go deeper on NK-GDT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK-GDT.